HOPA

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Jaime Anderson, PharmD, BCOP, reviewed recent efficacy and safety data on immune checkpoint inhibitor regimens in melanoma, and discussed disease-specific characteristics that may guide treatment-planning decisions.

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Dr Seddon provided attendees with an overview of FLT3-mutated AML, including currently available treatments, mechanisms of resistance, and future directions.

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Josiah Land, PharmD, BCOP, and Jacob Kettle, PharmD, BCOP, discussed the realities of using PD-L1 as a biomarker in oncology in the front- and second-line settings.

The United States may be in the midst of an opioid epidemic, but the undertreatment of pain remains an issue for patients with cancer.
Although transplantation offers cures or durable remissions for malignancies, relapse is a frequent occurrence in many diseases, and remains a major cause of mortality.
Despite significant progress in stem-cell transplantations over the past decade, graft-versus-host disease (GVHD) remains the leading cause of nonrelapse death in this patient population.
Precision medicine con­tinues to transform oncology, and it is not just the treatments that are changing.
According to the re­sults of a recent survey of hematopoietic stem-cell transplantation (HSCT) professionals, burnout is prevalent across all HSCT disciplines, with pharmacists showing the highest rates of burnout and moral distress.
The overtreatment or undertreatment of patients with cancer can have life-or-death implications.
Patrick J. Medina, PharmD, BCOP, is Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa.
Page 2 of 3
Results 11 - 20 of 23